Legal Representation
Attorney
Gretchen Stroud
USPTO Deadlines
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 27, 2009 | CORV | P | REVIEW OF CORRESPONDENCE COMPLETE | Loading... |
| Jul 21, 2009 | I | PAPER RECEIVED | Loading... | |
| Jun 15, 2009 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jun 15, 2009 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Sep 23, 2008 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Sep 23, 2008 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Sep 21, 2008 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Sep 21, 2008 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Apr 17, 2008 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Apr 8, 2008 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Apr 8, 2008 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Nov 13, 2007 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Aug 21, 2007 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 1, 2007 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| May 14, 2007 | ALIE | A | ASSIGNED TO LIE | Loading... |
| May 14, 2007 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Apr 26, 2007 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 25, 2007 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 9, 2007 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceuticals, namely, monoclonal antibodies and fragments therefor for therapeutic purposes, namely the treatment and diagnosis of cancer, proliferative cell diseases, autoimmune diseases, infectious diseases, inflammatory diseases and genetic diseases
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Pharmaceutical and biological product development for others relating to monoclonal antibodies; consultation in the field of pharmaceutical and biological product development relating to monoclonal antibodies
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
042